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Background: Persistent carriage of pneumococcal vaccine serotypes has occurred after introduction of PCV13
vaccination in Africa but the mechanisms are unclear. We tested the feasibility of using a human pneumococ-
cal challenge model in Malawi to understand immune correlates of protection against carriage and to trial
alternative vaccine candidates. We aimed to identify a dose of Streptococcus pneumoniae serotype 6B suffi-
cient to establish nasopharyngeal carriage in 40% of those nasally inoculated and evaluate nasal mucosal
immunity before and after experimental inoculation.
Methods: Healthy student volunteers were recruited and inoculated with saline, 20,000 CFU/naris or
80,000 CFU/naris of Streptococcus pneumoniae serotype 6B Post inoculation carriage was determined by nasal
sampling for bacterial culture and lytA PCR. Immunological responses were measured in serum and nasal
mucosal biopsies before and after bacterial inoculation.
Findings: Twenty-four subjects completed the feasibility protocol with minimal side effects. pneumococcal
carriage was established in 0/6, 3/9 and 4/9 subjects in the saline, 20,000 CFU/naris and 80,000 CFU/naris
groups, respectively. Incidental (natural) serotype carriage was common (7/24 participants carried non-6B
strains, 29.2%. Experimentally induced type 6B pneumococcal carriage was associated with pro-inflamma-
tory nasal mucosal responses prior to inoculation and altered mucosal recruitment of immune cells post bac-
terial challenge. There was no association with serum anti-capsular antibody.
Interpretation: The serotype 6B experimental human pneumococcal carriage model is feasible in Malawi and
can now be used to determine the immunological correlates of protection against carriage and vaccine effi-
cacy in this population.
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V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)1. Introduction
Even in the era of conjugate vaccines, 400,000 deaths in children
under 5 years were attributed to Streptococcus pneumoniae infectionin 2015 [1]. African countries were disproportionately impacted with
an estimated 2.4 million cases of invasive disease and 170,000 pneu-
mococcal-attributable deaths in this period [1]. There is a persistent
high burden of pneumococcal disease in both adults and children in
Malawi which was associated with high residual vaccine-serotype
(VT) pneumococcal carriage in children already vaccinated with 13-
valent pneumococcal conjugate vaccine (PCV-13) [2]. The immuno-
logical mechanism to explain high VT pneumococcal carriage preva-
lence is not understood, but high population density and infection
pressure are likely to be important.
For ten years, we have used an experimental human pneumococ-
cal carriage model in the United Kingdom to study mucosal immunity
Research in context
Evidence before this study
Experimental human pneumococcal carriage has been used to
measure humoral and cellular responses in mucosal and sys-
temic compartments and as a method to test new vaccines in
high income settings. However, the greatest burden of invasive
pneumococcal disease is found in low- and middle- income
countries, particularly in sub-Saharan Africa. Despite the roll
out of pneumococcal conjugate vaccines in Malawi, vaccine
serotype carriage remains high, leading to persistent popula-
tion transmission and constraining herd effects. This is particu-
larly problematic in the context of prevalent pneumococcal
disease vulnerable populations (e.g., people living with HIV and
adults exposed to excessive household air pollution and mal-
nourishment) who are not eligible for vaccination under the
WHO expanded programme on immunisation. There is cur-
rently poor understanding of the correlates of pneumococcal
immunity and vaccine efficacy in these settings. Our group has
conducted thirteen individual clinical studies with more than
1500 participants recruited in Liverpool, United Kingdom. A
placebo-controlled trial of PCV13 demonstrated a 78% reduced
carriage acquisition after nasal challenge in the United King-
dom. Multiple studies have demonstrated the safety of this pre-
dominantly asymptomatic colonisation model with mild
symptoms of rhinorrhoea, sore throat, earache, fever and mal-
aise infrequently reported.
Added value of this study
We report the establishment of a controlled human infection
model of Streptococcus pneumoniae in Malawi, a low-resourced
setting with high burden of invasive pneumococcal disease.
This model and associated standard operating procedures were
transferred from the United Kingdom. We showed that Mala-
wian adult healthy volunteers can be safely challenged with
serotype 6B pneumococcus, and that colonisation can be con-
firmed through classical microbiological culture of nasal wash.
These observations were supported by findings of microbiolog-
ical and immunological investigations
Implications of all the available evidence
Pneumococcal epidemiology in sub-Saharan Africa is character-
ised by higher rates of carriage and transmission than HIC set-
tings despite introduction of conjugate vaccines. We have
safely transferred this S. pneumoniae controlled human infec-
tion model to Malawi and this is now ready to be used as a plat-
form to understand host-pathogen interactions, evaluate
immune responses to current conjugate vaccines and test new
vaccine candidates.
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model has demonstrated that vaccination with PCV13 reduced subse-
quent pneumococcal carriage acquisition by 78% in a UK population
[3] and has provided important insights into the interactions
between pneumococcal and influenza infection [6]. From an immu-
nological perspective, the model has advanced our understanding of
pneumococcal disease pathogenesis including the critical role of
polysaccharide-specific memory B cells [7], nasal innate immunity
[8] and alveolar macrophages [9].
Given the knowledge gaps related to VT pneumococcal carriage in
high burden countries, we conducted a feasibility study to safely
establish experimental pneumococcal carriage in Malawi and usednovel nasal microbiopsy techniques to evaluate mucosal immunity
before and after experimental inoculation. This work aims to evaluate
which vaccines can prevent acquisition of pneumococcal carriage in
Malawi, and to determine the critical mechanisms of respiratory tract
defence that may be harnessed to develop more effective vaccines
suitable for low- and middle-income country use.
2. Methods
2.1. Study protocol and randomisation
This study adhered to a published protocol (https://wellcomeopen
research.org/articles/525)10. Briefly, healthy participants aged
1840 years consented to nasal inoculation of Streptococcus pneumo-
niae serotype 6B to determine the proportion who subsequently
developed colonisation. The majority of participants were undergrad-
uate students from adjacent university campuses. Fluency in written
Chichewa or English (to follow safety instructions) were inclusion cri-
teria but no other sampling frame restrictions were imposed [10]. A
detailed medical history and clinical examination was performed
during screening. Exclusion criteria included HIV seropositivity, preg-
nancy and colonisation with pneumococcal serotype 6B (other sero-
types permitted) at the screening visit.
We tested two doses of inoculum (20,000 and 80,000 colony
forming units per naris) in blocks of 12 participants, each block rand-
omised 3:1 with 9 participants receiving pneumococci and 3 receiv-
ing saline (0.9%). Rather than using a formal power calculation for
this feasibility study, we hypothesised that the infection rate in
Malawi would be similar to that in the UK and therefore that a dose
of 80,000 colony forming units per naris would be sufficient to estab-
lish nasal carriage in 4050% of participants [3]. We therefore
defined feasibility a priori as four or more participants in either dose
escalation group developing experimental carriage. This feasibility
study transferred an established technique where more than 1500
participants have been inoculated with pneumococci with well-
established carriage rates [10]. A secondary objective was to establish
the feasibility of immunological and diagnostic standardised operat-
ing procedures transferred from our UK model to Malawi.
2.2. Ethical approvals
The study was ethically approved in Malawi by the National
Health Sciences Research Committee (NHSRC, reference number: 19/
08/2246) and in the United Kingdom by the Liverpool School of Trop-
ical Medicine (LSTM, reference number: 19-017). LSTM also spon-
sored the study. Informed written consent was recorded for all
participants. Deidentified participant data will be made openly avail-
able one year after the publication date using the Harvard Dataverse
platform
2.3. Symptoms, sampling and endpoints
We determined participant symptoms including expected adverse
events with open and targeted questions at every clinic visit. Inter-
mittent sampling was performed for immunological analysis at
5 days before intranasal pneumococcal inoculation, and then on days
2, 7, and 14 afterwards: at these time points we collected nasal wash
for bacterial detection, peripheral blood, nasal scrapes and nasosorp-
tion samples. The primary endpoint was detection of the inoculated
pneumococci serotype (6B) by classical culture from nasal wash
recovered from the participants at any of days 2, 7 and 14 after pneu-
mococcal challenge. Nasal wash is established as the diagnostic tech-
nique from the Liverpool model due to the theoretical risk of
nasopharyngeal trauma and pneumococcal invasion from nasal
swabbing. In parallel, we confirmed carriage by detection of pneumo-
coccal lytA by PCR on nasal wash samples. Secondary endpoints were
B. Morton et al. / EBioMedicine 72 (2021) 103579 3symptoms, mucosal and systemic immune parameters. All subjects
completed exit questionnaires to assess study experience.
2.4. Preparation, inoculation and culture detection of pneumococcus
Briefly, as described in our study protocol [10], an aliquot of S.
pneumoniae serotype 6B BHN418 was thawed, centrifuged and
washed before being resuspended in 0.9% normal saline at the pre-
specified concentration (20,000 CFU/100 ml or 80,000 CFU/100 ml).
The prepared inoculum was taken immediately (less than 5 min tran-
sit) to the clinical area where 100 ml was instilled into each nostril of
the participant [3].
Nasal wash was collected as described elsewhere [3]. Briefly, 5 ml
of 0.9% saline was instilled into each naris; this was repeated twice
(10 ml per naris, 20 ml total). Samples were transported to the labo-
ratory and centrifuged at 3400 g for 10 min. Following centrifugation,
1 ml aliquots of the supernatant were stored at 80 °C. The nasal
wash bacterial pellet was resuspended in 100 ml of skim milk, tryp-
tone, glucose, and glycerine (STGG). Samples were retained for bacte-
rial culture and DNA extraction followed by lytA PCR.
To quantify colonization density by culture, serial dilutions of the
pellet, in 100 ml STGG, were plated on Columbia sheep Blood Agar
(Oxoid, UK) containing 4 mg/ml gentamicin (CBG). Plates were incu-
bated at 37 °C with 5% CO2 for 1824 h and inspected to identify
pneumococcal phenotype. Serotype (23-valent kit) was confirmed by
latex agglutination using Immulex Pneumotest reagents (Statens
serum institute).
2.5. Pneumococcal lytA PCR analysis
Genomic bacterial DNA was isolated from nasal wash pellets
stored in STGG using the Agowa Mag mini-DNA extraction kit (LGC
Genomics, Berlin, Germany) as per manufacturer’s instruction using a
300 ml aliquot of the stored nasal wash STGG pellet (the original
100 ml preparation was resuspended into 800 ml STGG and stored in
three aliquots). The eluted DNA was stored at 20 °C for use in lytA
qPCR. PCR amplification of the lytA gene was carried out using for-
ward primer (50-ACGCAATCTAGCAGATGAAGCA-30) and reverse
primer (50-TCGTGCGTTTTAATTCCAGCT-30). Master mix was prepared
using 12 ml of DEPC-treated H2O; 0.225 ml of each primer (100 mM);
0.125 ml of probe (100 mM); 12.5 ml of Taq. The total volume of PCR
reaction used was 25 ml, containing: 22.5 ml of the prepared master
mix and 2.5 ml of sample in a set of duplicate wells. Finally, 2.5 ml of
lytA plasmid (Fast-Track Diagnostics, Luxembourg) making up the
standard curve was added into each of two wells, beginning with the
lowest concentration standard (1 £ 10° copies/ml) to the highest con-
centration (1 £ 105 copies/ml). The plate was loaded in a thermocy-
cler (QuantStudio 7 Flex, Applied Bioscience) with the following
amplification conditions: 95 °C for 10 min; followed by 40 cycles of
95 °C for 15 s and then 60 °C for 1 min.
2.6. Nasal biopsy and flow cytometric mucosal immunophenotyping
Nasal microbiopsies were obtained from the inferior turbinate of
each participant using microcurettes without local analgesia. Each
sample was dropped immediately into transport medium and trans-
ferred to the laboratory in less than 10 min. For immunophenotyping,
nasal cells were dislodged from curettes by gentle pipetting and sus-
pension. Cells were then live-stained with an antibody cocktail con-
taining anti-human CD3 APC, anti-human CD19 Brilliant Violet 510,
TCR Gamma Delta FITC and anti-human CD45 Alexa Fluor 700 (all
BioLegend), anti-human CD14 PE-Cy7 (BD Biosciences), anti-human
CD66b PE (eBiosciences) and MR1 Tetramer Bv421
(NIH Tetramer Core Facility). After fixation, samples were acquired
using standard methods on an LSR FORTESSA flow cytometer (BD
Biosciences) and analysed using Flowjo v10.5.3 (BD Biosciences).2.7. Nasal lining fluid collection and luminex analysis of nasal fluid
cytokines
Nasosorption filters were gently applied to the nasal mucosa,
transferred in dry collection tubes and stored at 80 °C. Cytokines
were eluted from stored nasosorption filters (Mucosal Diagnostics,
Hunt Developments (UK) Ltd., Midhurst, UK) using 200 ml of elu-
tion buffer (Millipore) by centrifugation at 1500 g, then the eluate
was cleared by further centrifugation at 1595 g. The samples were
acquired on a MAGPIX (Luminex, UK) using a 38-plex magnetic
human cytokine kit (Millipore) and analysed with xPONENT software
following the manufacturer’s instructions. The analytes included
sCD40L, EGF, Eotaxin/CCL11, FGF-2, Flt-3 ligand, Fractalkine, G-CSF,
GM-CSF, GRO, IFN-a2, IFN-g , IL-1a, IL-1b, IL-1ra, IL-2, IL-3, IL-4, IL-5,
IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-
17A, IP-10, MCP-1, MCP-3, MDC (CCL22), MIP-1a, MIP-1b, TGF-a,
TNF-a, TNF-b and VEGF.
2.8. Anti-pneumococcal capsular polysaccharide (PS) ELISA
Anti-pneumococcal capsular PS antibodies were determined in
serum using the World Health Organization internationally standard-
ized method and reagents [7]. Briefly, 96-well ELISA plates were
coated using 5mg/mL of purified serotype 6B polysaccharide (Statens
Serum Institute) overnight at 4 °C. Plates were washed 3 times with
PBS containing 0.05% Tween-20 between each step. Wells were
blocked with 1% Bovine Serum Albumin in PBS for 2 h at room tem-
perature. Samples were diluted in PBS containing 5 mg/mL CWPS
Multi (Statens Serum Institute) and incubated for 30 min at 37 °C.
007sp reference serum received from NIBSC was used as a standard.
Diluted/adsorbed samples were then transferred to pre-coated plates
and incubated for 2 h at room temperature. Antibody detection was
performed using IgG-Horseradish Peroxidase and TMB substrate-
based platform. All samples were run in triplicate in four dilutions,
and samples with a CV of greater than 15% were repeated. Results are
expressed as mg/mL calculated using the assigned IgG concentrations
in reference serum 007sp.
2.9. Statistical analyses
Statistical analyses were performed using R v.4.0.2 (R Develop-
ment Core Team, Vienna, Austria) and GraphPad Prism v9.0.0 (Graph-
Pad Software, San Diego, California, USA). Non-normally distributed
quantitative measurements are summarised by the median and
inter-quartile range (IQR). Exact binomial confidence intervals are
reported for estimated proportions. Categorical variables were com-
pared using Fisher’s exact test. The nasal cell and serum IgG antibody
data were analysed using Friedman test with correction for multiple
comparisons using Dunn’s multiple comparisons test. A p-value of
<0.05 was considered statistically significant, all p-values are two-
tailed. All cytokine data were log10-transformed and summarised by
medians and IQRs.
2.10. Role of funding source
The funder and sponsor have no role in study design; collection,
management, analysis, and interpretation of data; writing of the
report; or the decision to submit the report for publication.
3. Results
3.1. Recruitment, inoculation and symptoms
Twenty-nine participants were screened and 24 inoculated (Fig. 1)
before the study met a priori defined stopping criteria [10]. Twelve
participants were randomised (3:1) to receive inoculation with S.
Fig. 1. CONSORT diagram. Figure demonstrates the number of participants screened and subsequently inoculated within the study. An additional two participants were screened
for the planned 160,000 CFU group but the study met pre-defined stopping criteria before inoculation [10].
4 B. Morton et al. / EBioMedicine 72 (2021) 103579pneumoniae serotype 6B strain BHN418 20,000 colony forming units
(cfu)/naris or normal saline (i.e. n = 9 randomised to S. pneumoniae
serotype 6B and n = 3 to normal saline) and 12 subjects were rando-
mised (also 3:1) to the higher inoculum of 80,000 cfu/naris or normal
saline (again n = 9 for S. pneumoniae and n = 3 for saline). All inocu-
lated participants completed the study follow up as per protocol, and
all reported a satisfactory experience. The study commenced Novem-
ber 2019 and was paused (at n = 20 recruited participants) due to the
emerging COVID-19 pandemic in March 2020. The study recom-
menced in October 2020 with additional safety procedures (including
COVID-19 testing and the provision of additional personal protective
equipment for research staff). Participant characteristics are
described in Table 1. Following inoculation, minor symptoms were
observed in 9/24 of inoculated participants, consistent with previ-
ously published work [12]. Whilst not statistically significant, we
noted that 4/6 participants (66.7%) inoculated with saline developed
symptoms, compared to 5/18 participants (27.8%) inoculated with
pneumococcus (Table 2). We also noted that there were more partici-
pants who smoked 2/9 and drank alcohol 6/9 in the 80,000 CFU group
(Table 1). These observations require follow up in future studies.
3.2. Primary endpoint pneumococcal carriage and incidental non-
experimental carriage
Inoculation with pneumococcal serotype 6B, resulted in 3/9 (33%
[CI 770]) and 4/9 (44% [CI 1479]) of participants developing nasalTable 1
Participant demographics. BMI: body mass index.
All (n = 24) Control
Age [median (IQR)] 23 (22,25) 24 (23,2
Sex [male (%)] 20 (83.3) 5 (83.3)
Current smoker [n (%)] 2 (8.3) 0 (0.0)
Occasional alcohol [n (%)] 9 (37.5) 0 (0.0)
BMI [median (IQR)] 22.9 (20.3,24.2) 23.3 (19
Both current smokers both smoked less than five cigarettes
two participants had given up smoking more than six montcolonisation, in the 20,000 CFU and 80,000 CFU groups, respectively.
The inoculation doses (median (IQR) of serotype 6B were 21,834
(19,50022,333) and 91,667 (88,334100,000) for the 20,000 and
80,000 CFU groups, respectively. The prevalence of incidental car-
riage was relatively common with non-6B serotypes identified in 7/
24 (29.2% [1351]) participants (Fig. 2) These included both vaccine
serotypes (7, 1719) and non-vaccine serotypes (found in 9 samples
from 3 participants). One of these participants demonstrated sero-
type 18 carriage during screening and was subsequently colonised
with 6B after nasal challenge. A full description of nasal wash results
including culture (CFU/100 ml) and lytA density (copies per ml) is
provided in the supplementary material (Table S1). We found high
concordance between classic microbiological culture and lytA PCR
positivity for S. pneumoniae (84 out of 96 concordant samples, 87.5%).
Serotype 6B specific concordance could not be calculated as lytA
detection cannot distinguish different serotypes.
3.3. Cellular infiltration of the nasal mucosa following pneumococcal
challenge
Immune responses induced by respiratory pathogens are gener-
ally compartmentalised to the respiratory mucosa [13,14]. We there-
fore sought to explore whether nasal pneumococcal challenge or
carriage induced cellular responses in the nasal mucosa, and if they
are associated with development of pneumococcal carriage. We mea-
sured the changes in numbers and proportions of immune cells(n = 6) 20,000 CFU (n = 9) 80,000 CFU (n = 9)
6) 23 (20,25) 23 (22,24)
7 (77.8) 8 (88.9)
0 (0.0) 2 (22.2)
3 (33.3) 6 (66.7)
.0,24.0) 22.7 (19.9,23.1) 23.1 (21.1,26.6)
per day. Twenty participants had never smoked, and
hs previously with less than 10 pack years.
Table 2
Participant symptoms after inoculation. Participants were specifically asked if they had experienced listed symptoms at each follow up visit after
inoculation. “Other” symptoms were: one episode of vomiting thought to be related to food, one episode of non-specific tiredness and one episode of
“wet nose at night-time”. Symptoms reported within the table represent aggregated data from participants during symptom screening two, seven and
fourteen days after inoculation. Participants classified as colonised with 6B if this serotype was detected in any nasal wash sample two, seven and four-
teen days after inoculation.
n Total AEs Sore throat Coryzal symptoms Headache Earache Feverish Cough Rash Other
All 24 9 0 3 2 0 0 0 1 3
Control 6 4 0 2 2 0 0 0 0 0
20,000 CFU 9 4 0 1 0 0 0 0 0 3
80,000 CFU 9 1 0 0 0 0 0 0 1 0
Colonised (6B) 7 2 0 1 0 0 0 0 0 1
Colonised (not 6B) 6 2 0 0 0 0 0 0 1 1
Not colonised 11 5 0 2 2 0 0 0 0 1
B. Morton et al. / EBioMedicine 72 (2021) 103579 5collected using nasal curettes from the nasal mucosa. Nasal scrapes
collected per individual for immunophenotyping resulted in a cell
yield of 27,500 cells/scrape [IQR 22,500-37,500]. The number of
immune cells increased between baseline and day 7 post pneumo-
coccal challenge in carriage negative individuals (p = 0.012, Friedman
test with Dunn correction), but this was not observed in the experi-
mental carriage positive individuals or those that received normal
saline (Fig. 3a). Moreover, the number of immune cells was higher at
day 7 in the carriage negative individuals compared to the carriage
positive individuals (p = 0.012, Kruskal-Wallis with Dunn’s correc-
tion), but was similar with those that received normal salineFig. 2. Pneumococcal detection from nasal wash. Figure demonstrates the proportions (w
(panel b) in participants from the control, 20,000 and 80,000 CFU/naris groups. Presence of a
in panels c and d.(p = 0.533, Kruskal-Wallis with Dunn’s correction) (Fig. 3a). Neutro-
phils and T cells were the predominant immune cells in nasal muco-
sal samples (Supplementary Fig. 1), hence we focused our analysis on
these major immune cells. The neutrophil to T cell ratio increased
between baseline and day 7 in all study groups, but the difference
was only statistically significant in the in carriage negative individu-
als (p < 0.001, Friedman test with Dunn correction) (Fig. 3bc), likely
due to the small sample size. An analysis on the absolute numbers
also showed an increase in numbers of neutrophils between baseline
and day 7 in all the study groups, but this was also only statistically
significant in the in carriage negative individuals (p = 0.004, Friedmanith confidence intervals) of pneumococcal serotype 6B (panel a) and non-6B carriage
ny pneumococcal nasal carriage was determined by both culture and lytA PCR as shown
Fig. 3. Nasal cellular immune responses before and following inoculation. Nasal cells were collected by mucosal scraping with rhinoprobes. A cell scrape from each nostril were
combined for flow cytometry-based immunophenotyping. (a) Total absolute cell counts from the cell scrapes at different time points showed increased cells at day 7 in the group
that did not develop carriage with uniform collections at other points. (b) Neutrophil to T cell ratio from the flow cytometry based immunophenotyping shows increase in carriage
negative group at day 7. (c) Absolute neutrophil counts from the cell scrapes at different time points by experimental condition. (d) Absolute T cell counts from the cell scrapes at dif-
ferent time points by experimental condition showing no difference. The horizontal bars represent the median and interquartile range (IQR). Data were analysed using Friedman
test with correction for multiple test using Dunn’s multiple comparisons test, comparing baseline to day 2, 7 and 14 within each study group (Carriage positive, n = 7; Carriage nega-
tive, n = 11; Saline controls, n = 6). SPN, Streptococcus pneumoniae.
6 B. Morton et al. / EBioMedicine 72 (2021) 103579test with Dunn correction) (Fig. 3d), suggesting that baseline sam-
pling may have induced infiltration of neutrophils to the nasal
mucosa. In contrast, no changes were observed in nasal T cell num-
bers between baseline and day 7 in all the study groups (Fig. 3d). In
addition, there were no differences in the frequencies of B cells, GD T
cells, MAIT cells and monocytes overtime and across the study groups
(data not shown). Together, these results suggest that an attenuated
cellular infiltration in the nasal mucosa may be associated with suc-
cessful experimental introduction of pneumococcal serotype 6B car-
riage.
3.4. Association of nasal cytokine environment at inoculation and
subsequent development of carriage
Nasal inflammation has been associated with increased propen-
sity for experimental pneumococcal carriage [8] and carriage in chil-
dren in Kenya [15]. We therefore sought to explore whether the
baseline cytokine environment before pneumococcal challenge influ-
enced subsequent development of pneumococcal carriage in our
model. Concentrations of 37 cytokines and sCD40L were measured in
nasal lining fluid (Supplementary Fig. 2). Concentrations of Flt-3 L, IL-
3 and TNF-b were not detectable in any of the samples. There was a
trend towards higher levels of IFN-a2, IL-6, GM-CSF, IL12p40, IFN-g ,
IL-10, sCD40L, IL-12p70, IL-15, MIP-1b and IL-1b at baseline (day
5), in those subjects that eventually successfully developed experi-
mental pneumococcal carriage (carriage positive) compared to thosethat did not (carriage negative) or subjects given saline as controls
(Fig. 4 and Supplementary Fig. 2). Further work in larger cohorts is
required to elucidate cytokine changes that occur in response to inoc-
ulation. The findings do suggest that an inflammatory nasal cytokine
microenvironment prior to inoculation may indeed be associated
with successful development of serotype 6B carriage.
3.5. Nasal pneumococcal challenge or carriage did not elicit an increase
in serum anti-6B polysaccharide igG antibodies
Serum anti-6B polysaccharide IgG antibody levels have been
shown to increase in subjects that establish pneumococcal carriage
following nasal experimental challenge with serotype 6B [7]. We
measured the levels of anti-6B polysaccharide IgG antibodies in
serum before (day 5) and after (day 2, 7 and 14) inoculation with
normal saline or pneumococcal serotype 6B There was no difference
between groups at baseline and we did not observe an increase in
the serum anti-6B polysaccharide IgG antibody levels in those that
were inoculated compared to those that were not, irrespective of the
serotype 6B carriage status (all p > 0.05, Friedman test with Dunn
correction). These findings suggest that experimental nasal pneumo-
coccal challenge or experimental human pneumococcal carriage did
not induce serum anti-6B polysaccharide IgG levels beyond natural
exposure in this setting (Fig. 5). Further work with larger numbers of
subjects will be required to determine if small rises in IgG are
induced by experimental carriage.
Fig. 4. . Nasal cytokine responses before and following inoculation. Nasal lining fluid was collected using nasosorption filters. Nasal lining fluid was eluted from nasosorption fil-
ters and cytokines were measured using a 38-plex magnetic human cytokine kit. The data was log 10 transformed and plotted on a heatmap as median concentrations of selected
cytokines in nasal lining fluid among the study groups, at multiple time points. Blue represents low concentration and red represents high concentrations. The data from day 5 in
each panel show that the group developing carriage (middle panel) had higher median levels of inflammatory cytokines that the group who did not develop carriage (left hand
panel). Saline controls were intermediate as expected. Carriage positive, n = 7; Carriage negative, n = 11; Saline controls, n = 6. SPN, Streptococcus pneumoniae. (For interpretation of
the references to color in this figure legend, the reader is referred to the web version of this article).
B. Morton et al. / EBioMedicine 72 (2021) 103579 74. Discussion
This study has shown for the first time that experimental human
pneumococcal carriage can be safely carried out in Malawi. Malawi
has very different pneumococcal epidemiology and biology com-
pared to Europe likely underpinned by differences in human-patho-
gen interaction as well as the physical environment, and socio-
economic circumstances including the effects of crowding. OurFig. 5. Anti-6B polysaccharide IgG antibodies in serum before and following inocu-
lation. Levels of polysaccharide 6B (PS6B)-specific IgG antibodies in serum were mea-
sured using an enzyme-linked immunosorbert assay (ELISA). The serum samples were
from volunteers experimentally inoculated with Streptococcus pneumoniae 6B, and those
who received a normal saline as a control. The S. pneumoniae inoculated volunteers
were further subdivided into carriage positive (carriage+) and carriage negative (car-
riage-). The serum samples were obtained before (Day 5) and after (Days 3, 7, and 14)
inoculation. The horizontal bars represent the median and interquartile range (IQR).
Data were analysed using Friedman test with correction for multiple test using Dunn’s
multiple comparisons test, comparing baseline to day 2, 7 and 14 within each study
group (Carriage positive, n = 7; Carriage negative, n = 11; Saline controls, n = 6). There
were no significant differences in IgG level in any experimental condition or at any time
point. One individual from the Saline control group does not have a serum IgG result at
Day 5 and Day 2. IgG, immunoglobulin G; SPN, Streptococcus pneumoniae.primary objective was achieved in that our study showed that
recruitment, screening of volunteers and safe completion of the study
per protocol was feasible with local adaptation of the protocol ini-
tially developed in the UK. Observed carriage rates were consistent
with that observed in the UK and the model behaved similarly. There
were no specific local difficulties with recruitment, inoculum was
delivered accurately and safely and the rates of experimental pneu-
mococcal carriage mirrored those from our Europe-based studies.
Our secondary objectives were to measure carriage symptoms
and to determine if immunological sampling would be possible in
sufficient yield to study key differences in carriage epidemiology
observed between the UK and Malawi [16]. As in Europe, we found
experimental human pneumococcal carriage to be asymptomatic.
Nasal fluid collection by nasosorption, nasal micro-biopsy and nasal
wash were all well tolerated and full sample sets well collected from
all subjects. As the sampling was successful, we were able to compare
several immunological parameters between subjects who experi-
enced experimental carriage and those who did not, as well as saline
controls. These data showed evidence that experimental carriage fol-
lowing inoculation was associated with a specific baseline inflamma-
tory milieu, and that the clearance of inoculum without
establishment of carriage was associated with robust cellular infiltra-
tion of the nasal mucosa in day 7 (post-inoculation) samples. Further
work is required in a larger sample to establish the relationship with
cellular and cytokine responses. We did not find evidence that estab-
lishment of carriage was associated with baseline anti-capsular IgG
nor did experimental carriage induce any increase in serum anti-cap-
sular IgG.
This study in Malawi shows some similarity with work previously
published from Liverpool, UK. The predominantly student population
had no difficulty in completing the protocol [17]. The observed exper-
imental pneumococcal carriage rate, albeit in small numbers so far,
was similar to that observed in the UK [4]. The lack of specific symp-
toms for participants who developed experimental carriage were
also as expected [5]. The observed association of inflammation with
increased carriage rate was supportive of the observation in the UK
that viral co-infection was associated with increased carriage [18].
8 B. Morton et al. / EBioMedicine 72 (2021) 103579This observation will be followed up with further studies of coinci-
dent asymptomatic viral infection in Malawi. The lack of association
of experimental carriage with serum IgG was consistent with UK
results [19] which showed that circulating B cells rather than serum
IgG levels were associated with protection from carriage.
There were, however, some important differences in our study
from the UK experience and from our expected results. The baseline
and incidental naturally acquired pneumococcal carriage rate were
higher than that in Liverpool, and so the usefulness of lytA PCR as a
confirmatory method of determining carriage was much lower than
in the UK. The frequency of naturally acquired carriage episodes in
Malawi is therefore a factor that must be considered in experimental
design using the human challenge model in future studies. Specifi-
cally, it may be important to use molecular methods to characterise
the several serotypes present in the nasopharynx. It was surprising,
however, that we saw no evidence of increased experimental car-
riage in those participants already experiencing natural carriage as
our previous studies of the nasal microbiome suggested a “carriage
tolerant” phenotype in participants with pre-existing pneumococcal
colonisation [20]. This result will need to be further explored with
larger numbers of subjects. It may also be useful to explore controlled
human infection with pneumococcal serotypes that are more com-
monly found in Malawi.
The main strength of this study is that it shows experimental
human pneumococcal carriage to be feasible in Africa, a continent
with a residual burden of pneumococcal disease that may not be con-
trolled by current conjugate vaccination strategy. A further strength
of the study is that we piloted the use of sophisticated mucosal analy-
ses to unpick immunological differences between Europe and Africa.
This feasibility study has generated a number of hypotheses that
should now be tested in larger cohorts, most important being the
association of nasal mucosal inflammation with frequent pneumo-
coccal carriage.
The main limitations in this study are related to the small num-
bers of participants. Larger studies will confirm that the rate of
reported symptoms remain low. Further, we achieved accurate chal-
lenge dosing of controlled shipment from Liverpool [3,11]. It remains
our goal to manage the entire production of the inoculum in Malawi
in due course. The rate of infection will be confirmed in larger num-
bers of subjects as will the immunological observations in this cohort.
We acknowledge that participant self-reporting or recall bias may be
a potential limitation of this study, but participants (and clinical
researchers) were blinded to inoculation allocation (saline vs. pneu-
mococci) so this should not have influenced differentially observed
reporting between these groups. In future studies, we will incorpo-
rate the use of multiplex lytA/6B PCR as lytA detection alone could
not distinguish the different serotypes hence not being able to calcu-
late serotype 6B specific concordance between culture and PCR. We
have confirmed that the experimental human pneumococcal chal-
lenge model may now be used in Malawi to test novel vaccines, and
to explore the differences that underpin the observed differences in
epidemiology.
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